|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.33 USD | +0.14% |
|
+0.35% | +0.63% |
| Capitalization | 4.43B 3.82B 3.56B 3.31B 6.17B 402B 6.63B 40.92B 16.13B 192B 16.62B 16.28B 700B | P/E ratio 2025 * |
-614x | P/E ratio 2026 * | 52.4x |
|---|---|---|---|---|---|
| Enterprise value | 4.52B 3.9B 3.63B 3.38B 6.29B 411B 6.77B 41.77B 16.47B 196B 16.97B 16.62B 715B | EV / Sales 2025 * |
7.19x | EV / Sales 2026 * | 5.87x |
| Free-Float |
89.87% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Amicus Therapeutics, Inc.
| 1 day | +0.14% | ||
| 1 week | +0.35% | ||
| Current month | +0.63% | ||
| 1 month | +31.59% | ||
| 3 months | +78.23% | ||
| 6 months | +140.44% | ||
| Current year | +0.63% |
| 1 week | 14.27 |  | 14.38 |
| 1 month | 14.18 | | 14.38 |
| Current year | 14.2 | | 14.38 |
| 1 year | 5.51 | | 14.38 |
| 3 years | 5.51 | | 14.57 |
| 5 years | 5.51 | | 22.15 |
| 10 years | 4.41 | | 25.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Bradley Campbell
CEO | Chief Executive Officer | 50 | 31/07/2022 |
Simon Harford
DFI | Director of Finance/CFO | 65 | 20/08/2023 |
Pat O’Sullivan
COO | Chief Operating Officer | - | 30/06/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Mike Raab
CHM | Chairman | 61 | 03/03/2024 |
Glenn Sblendorio
BRD | Director/Board Member | 70 | 31/05/2006 |
Bradley Campbell
BRD | Director/Board Member | 50 | 07/06/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.14% | +0.35% | +52.28% | +9.39% | 4.43B | |
| -0.89% | +1.01% | +0.87% | +12.40% | 48.93B | |
| -1.49% | -1.95% | +20.43% | +7.77% | 40.48B | |
| -0.03% | +0.09% | +60.98% | +27.62% | 37.42B | |
| -0.71% | -3.69% | +20.76% | +39.16% | 31.03B | |
| -2.43% | +1.38% | +198.54% | +337.70% | 23.25B | |
| -1.16% | +2.67% | +81.09% | +163.02% | 17.21B | |
| Average | -0.94% | +0.17% | +62.13% | +85.29% | 28.97B | |
| Weighted average by Cap. | -1.00% | -0.09% | +49.51% | +68.40% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 629M 542M 505M 470M 875M 57.09B 942M 5.81B 2.29B 27.23B 2.36B 2.31B 99.44B | 745M 643M 598M 557M 1.04B 67.63B 1.12B 6.88B 2.71B 32.26B 2.8B 2.74B 118B |
| Net income | -7.86M -6.78M -6.31M -5.88M -10.94M -714M -11.77M -72.6M -28.63M -340M -29.49M -28.89M -1.24B | 85.32M 73.56M 68.48M 63.75M 119M 7.74B 128M 788M 311M 3.69B 320M 313M 13.48B |
| Net Debt | 92.44M 79.69M 74.18M 69.06M 129M 8.39B 138M 853M 336M 4B 347M 340M 14.61B | -57.88M -49.9M -46.45M -43.25M -80.52M -5.25B -86.63M -534M -211M -2.51B -217M -213M -9.15B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/01/26 | 14.33 $ | +0.14% | 3,535,915 |
| 15/01/26 | 14.31 $ | -0.49% | 5,199,911 |
| 14/01/26 | 14.38 $ | +0.42% | 9,893,903 |
| 13/01/26 | 14.32 $ | +0.28% | 9,172,324 |
| 12/01/26 | 14.28 $ | 0.00% | 11,700,468 |
Delayed Quote Nasdaq, January 16, 2026 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- FOLD Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition